Stada Arzneimittel AG (SAZ) – Financial and Strategic SWOT Analysis Review

Stada Arzneimittel AG (SAZ) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
52
Pharmaceuticals and Healthcare
Germany

Stada Arzneimittel AG (SAZ) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

STADA Arzneimittel AG (STADA) is a pharmaceutical company. The company develops and markets off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. The company offers active-ingredient generic products; and branded products which focus on outsource products that are accessible without active ingredient research. Major generic products include including Omeprazole, Enalapril, Phospholipide, Pantoprazol and Diclofenac. The company operates in 29 countries with 47 sales companies in major regions of Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific.

Stada Arzneimittel AG Key Recent Developments

Feb 19, 2015 STADA: Sales and earnings targets for 2014 at Group level met
Dec 15, 2014 German Pharmaceutical Companies Appeal Suspensions Of Drugs Tested By GVK Biosciences
Nov 13, 2014 STADA Announces Financial Results For The Fiscal Year 2014
Sep 16, 2014 STADA expands branded product strategy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Stada Arzneimittel AG – Key Facts 6
Stada Arzneimittel AG – Key Employees 7
Stada Arzneimittel AG – Key Employee Biographies 8
Stada Arzneimittel AG – Major Products and Services 9
Stada Arzneimittel AG – History 10
Stada Arzneimittel AG – Company Statement 14
Stada Arzneimittel AG – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 18
Stada Arzneimittel AG – Business Description 18
Stada Arzneimittel AG – Corporate Strategy 19
Stada Arzneimittel AG – SWOT Analysis 20
SWOT Analysis – Overview 20
Stada Arzneimittel AG – Strengths 20
Strength – Product Portfolio 20
Strength – Improvement in Profitability Indicators 20
Strength – Wide Geographic Presence 20
Stada Arzneimittel AG – Weaknesses 21
Weakness – Highly Leveraged 21
Stada Arzneimittel AG – Opportunities 22
Opportunity – New Product Approvals and Launches 22
Opportunity – Business Initiatives 22
Opportunity – Rising Healthcare Expenditure 22
Stada Arzneimittel AG – Threats 23
Threat – Competitive Pressures 23
Threat – Growing Parallel Trade 23
Threat – Increased Scrutiny on Imports 23
Stada Arzneimittel AG – Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios – Capital Market Ratios 25
Financial Ratios – Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 31
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 32
Stada Arzneimittel AG, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Feb 19, 2015: STADA: Sales and earnings targets for 2014 at Group level met 34
Dec 15, 2014: German Pharmaceutical Companies Appeal Suspensions Of Drugs Tested By GVK Biosciences 35
Nov 13, 2014: STADA Announces Financial Results For The Fiscal Year 2014 36
Sep 16, 2014: STADA expands branded product strategy 38
Aug 07, 2014: STADA Provides Business Update 39
May 08, 2014: STADA with positive development in the first quarter of 2014 – Group sales rise by 7 percent – reported EBITDA and reported net income slightly over previous year level despite CIS crisis 41
Mar 24, 2014: STADA Arzneimittel Announces Results For Financial Year 2013 43
Mar 03, 2014: Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed 45
Feb 14, 2014: STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel 46
Jan 22, 2014: STADA exceeds two-billion-euro mark in sales 47
Section 6 – Appendix 48
Methodology 48
Ratio Definitions 48
About GlobalData 52
Contact Us 52
Disclaimer 52



List of Tables
Stada Arzneimittel AG, Key Facts 6
Stada Arzneimittel AG, Key Employees 7
Stada Arzneimittel AG, Key Employee Biographies 8
Stada Arzneimittel AG, Major Products and Services 9
Stada Arzneimittel AG, History 10
Stada Arzneimittel AG, Other Locations 15
Stada Arzneimittel AG, Subsidiaries 15
Stada Arzneimittel AG, Key Competitors 24
Stada Arzneimittel AG, Ratios based on current share price 25
Stada Arzneimittel AG, Annual Ratios 26
Stada Arzneimittel AG, Interim Ratios 29
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 31
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 32
Stada Arzneimittel AG, Recent Deals Summary 33
Currency Codes 48
Capital Market Ratios 48
Equity Ratios 49
Profitability Ratios 49
Cost Ratios 50
Liquidity Ratios 50
Leverage Ratios 51
Efficiency Ratios 51



List of Figures
Stada Arzneimittel AG, Performance Chart (2009 – 2013) 28
Stada Arzneimittel AG, Ratio Charts 30
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 31
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 32

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.